[ad_1]
Operator
Good afternoon, girls and gents, and welcome to the Avacta Group plc Interim Outcomes Investor Presentation. [Operator Instructions] Because of the vital attendance on right this moment’s name, the corporate won’t be ready to reply each query obtained throughout the assembly itself. Nevertheless, the corporate can evaluate all questions submitted right this moment, and can publish these responses the place it is applicable to take action.
Earlier than we start, we would prefer to submit the next ballot. And I am positive the corporate shall be most grateful on your participation.
I might now like handy over to the administration crew, Chris, Brian. Good afternoon.
Christina Coughlin
CEO & Government Director
Good afternoon, Mark. Thanks for having us, and good morning to our colleagues throughout the pond in states. My identify is Christina Coughlin. I’m the CEO of Avacta Therapeutics coming to you right here from White Metropolis, London at our headquarters, and I am joined by my Chief Monetary Officer, Brian Hahn. We look ahead to delivering to you right this moment our interim outcomes for the interval ending June 30, 2025. As a part of our presentation, each Brian and I shall be making forward-looking statements.
Latest analysis and improvement highlights from the corporate. We’re at the moment enrolling our medical stage program, faridoxorubicin, joyful to deliver that identify to you for the primary time right this moment. It has been issued by the World Well being Group, FAP-Dox or AVA6000. We proceed to enroll within the growth cohorts on this program.
Our second medical program, and I exploit that time period as FAP-exatecan, is shortly approaching the clinic. FAP-exatecan does stay on monitor to dose its first affected person within the first quarter
[ad_2]
